000278420 001__ 278420
000278420 005__ 20240229155035.0
000278420 0247_ $$2doi$$a10.1002/cam4.6436
000278420 0247_ $$2pmid$$apmid:37578395
000278420 0247_ $$2altmetric$$aaltmetric:152974221
000278420 037__ $$aDKFZ-2023-01654
000278420 041__ $$aEnglish
000278420 082__ $$a610
000278420 1001_ $$aZitricky, Frantisek$$b0
000278420 245__ $$aConditional survival in breast cancer up to 10 years in the Nordic countries.
000278420 260__ $$aHoboken, NJ$$bWiley$$c2023
000278420 3367_ $$2DRIVER$$aarticle
000278420 3367_ $$2DataCite$$aOutput Types/Journal article
000278420 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695974093_24399
000278420 3367_ $$2BibTeX$$aARTICLE
000278420 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278420 3367_ $$00$$2EndNote$$aJournal Article
000278420 500__ $$a#LA:C020# / 2023 Sep;12(17):17945-17951
000278420 520__ $$aSurvival in breast cancer (BC) has developed favorably but late recurrences are still a problem.We model survival data from the NORDCAN database and analyze 1-, 5-, and 10-year relative survival and 5/1- and 10/5-year conditional survival in BC from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) between 1971 and 2020. Conditional survival measures survival in those who had survived year 1 to reach year 5 (5/1), or in those who had survived year 5 to reach year 10 (10/5).Almost all survival metrics were best for SE but survival in all countries improved in the course of time approaching the SE levels which were 98.3% for 1-year, 92.3% for 5-year, and 87.8% for 10-year survival. Conditional 10/5-year survival, covering 5 years, was better than 5/1-year survival, covering 4 years. A contributing factor is most likely the high rate of recurrence in period 2-5 years. The difference was observed for all countries but for DK 10/5-year survival approached 1-year survival and for NO and SE 10/5-year survival was only barely better than 5/1-year survival. The explanation to this was the excellent 10/5-year survival in DK compared to SE and particularly to NO. Literature search suggested that the reason for the relatively low 10/5-year survival in NO might be stagnant survival development in old patients.We assume that late mortality is critically limiting survival in BC and either interference with the late metastatic process or effective treatment will be key to future improvements in BC survival.
000278420 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000278420 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000278420 650_7 $$2Other$$aconditional survival
000278420 650_7 $$2Other$$ametastasis
000278420 650_7 $$2Other$$aperiodic survival
000278420 650_7 $$2Other$$arecurrence
000278420 650_7 $$2Other$$ascreening
000278420 650_7 $$2Other$$atreatment
000278420 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000278420 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b2
000278420 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b3$$eLast author$$udkfz
000278420 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.6436$$gp. cam4.6436$$n17$$p17945-17951$$tCancer medicine$$v12$$x2045-7634$$y2023
000278420 909CO $$ooai:inrepo02.dkfz.de:278420$$pVDB
000278420 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000278420 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000278420 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000278420 9141_ $$y2023
000278420 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:13Z
000278420 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:13Z
000278420 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-04-16T15:13:13Z
000278420 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-30
000278420 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000278420 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000278420 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000278420 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000278420 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2021-04-16T15:13:13Z
000278420 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000278420 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000278420 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000278420 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000278420 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000278420 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000278420 980__ $$ajournal
000278420 980__ $$aVDB
000278420 980__ $$aI:(DE-He78)B062-20160331
000278420 980__ $$aI:(DE-He78)HD01-20160331
000278420 980__ $$aI:(DE-He78)C020-20160331
000278420 980__ $$aUNRESTRICTED